248 related articles for article (PubMed ID: 25209137)
1. Proton pump inhibitors and risk of bone fractures.
Leontiadis GI; Moayyedi P
Curr Treat Options Gastroenterol; 2014 Dec; 12(4):414-23. PubMed ID: 25209137
[TBL] [Abstract][Full Text] [Related]
2. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
3. [Proton pump inhibitor and bone complications].
Soen S
Clin Calcium; 2015 Nov; 25(11):1667-74. PubMed ID: 26503872
[TBL] [Abstract][Full Text] [Related]
4. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
7. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
8. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
9. Proton pump inhibitors therapy and risk of bone diseases: An update meta-analysis.
Liu J; Li X; Fan L; Yang J; Wang J; Sun J; Wang Z
Life Sci; 2019 Feb; 218():213-223. PubMed ID: 30605646
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Fournier MR; Targownik LE; Leslie WD
Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
[TBL] [Abstract][Full Text] [Related]
12. Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study.
Lewis JR; Barre D; Zhu K; Ivey KL; Lim EM; Hughes J; Prince RL
J Bone Miner Res; 2014 Nov; 29(11):2489-97. PubMed ID: 24825180
[TBL] [Abstract][Full Text] [Related]
13. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
14. Use of Proton Pump Inhibitors and Risk of Fracture in Adults: A Review of Literature.
Paudel Y; Najam B; Desai HN; Illango J; Seffah KD; Kumar M; Naveen N; Pachchipulusu VK; Penumetcha SS
Cureus; 2023 Dec; 15(12):e49872. PubMed ID: 38170137
[TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.
Abrahamsen B; Vestergaard P
Bone; 2013 Nov; 57(1):269-71. PubMed ID: 23973557
[TBL] [Abstract][Full Text] [Related]
17. Recent safety concerns with proton pump inhibitors.
Chen J; Yuan YC; Leontiadis GI; Howden CW
J Clin Gastroenterol; 2012 Feb; 46(2):93-114. PubMed ID: 22227731
[TBL] [Abstract][Full Text] [Related]
18. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
19. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
